{'fraction_non_alphanumeric': 0.024475524475524476, 'fraction_numerical': 0.013111888111888112, 'mean_word_length': 4.963541666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bcl-2 Over-Expression and Genetic Manipulation of T Cells Provides Tumor Specificity and Enhanced Resistance to Apoptosis In Vitro

Adoptive immunotherapy using T cells has produced some encouraging clinical responses, but deficiencies resulting from a frequent lack of tumor specificity and poor survival of these cells has limited the widespread application of this approach. We used a chimeric receptor gene specific for erbB2 in T cells with genetic resistance to apoptosis to address these deficiencies. Expression of the chimeric receptor was found to be equivalent in T cells from bcl-2 transgenic-, lpr- and wild-type C57BL/6 mice. Furthermore, T cells from each mouse strain secreted similar amounts of IFN-� in response to erbB2, and lysed erbB2 + tumor cells to a similar degree. Interestingly, we demonstrated that erbB2-specific T cells from Bcl-2 transgenic mice have enhanced expansion in vitro compared to T cells from C57BL/6 and Lpr mice. In addition, transduced T cells from Bcl-2 transgenic mice demonstrated increased resistance to apoptosis following activation or cytokine withdrawal, when compared to Lpr and BL/6 cells.